Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K.

Mol Cancer Res. 2017 Jan;15(1):45-58. doi: 10.1158/1541-7786.MCR-16-0157. Epub 2016 Sep 26.

2.

AXL-Driven EMT State as a Targetable Conduit in Cancer.

Antony J, Huang RY.

Cancer Res. 2017 Jul 15;77(14):3725-3732. doi: 10.1158/0008-5472.CAN-17-0392. Epub 2017 Jun 30. Review.

3.

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.

McDaniel NK, Cummings CT, Iida M, Hülse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, Harari PM, Kimple RJ, DeRyckere D, Graham DK, Wheeler DL.

Mol Cancer Ther. 2018 Nov;17(11):2297-2308. doi: 10.1158/1535-7163.MCT-17-1239. Epub 2018 Aug 9.

4.

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

Lin JZ, Wang ZJ, De W, Zheng M, Xu WZ, Wu HF, Armstrong A, Zhu JG.

Oncotarget. 2017 Jun 20;8(25):41064-41077. doi: 10.18632/oncotarget.17026.

5.

The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.

Wu F, Li J, Jang C, Wang J, Xiong J.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6653-61. eCollection 2014.

6.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

7.

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.

Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J.

Cancer Res. 2014 Oct 15;74(20):5878-90. doi: 10.1158/0008-5472.CAN-14-1009. Epub 2014 Aug 14.

8.

Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B.

Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6.

9.

AXL kinase as a novel target for cancer therapy.

Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B.

Oncotarget. 2014 Oct 30;5(20):9546-63. Review.

10.

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.

Bansal N, Mishra PJ, Stein M, DiPaola RS, Bertino JR.

Oncotarget. 2015 Jun 20;6(17):15321-31.

11.

Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.

Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ.

Mol Cancer Ther. 2013 Nov;12(11):2541-58. doi: 10.1158/1535-7163.MCT-13-0170. Epub 2013 Sep 11.

12.

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.

Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL.

Oncogene. 2014 Mar 6;33(10):1316-24. doi: 10.1038/onc.2013.57. Epub 2013 Mar 11.

13.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.

Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.

14.

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.

von Mässenhausen A, Brägelmann J, Billig H, Thewes B, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Brossart P, Kirfel J, Perner S.

Int J Mol Sci. 2016 Dec 22;18(1). pii: E7. doi: 10.3390/ijms18010007.

15.

Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.

Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, Torka R.

Cancer Biol Ther. 2014;15(11):1571-82. doi: 10.4161/15384047.2014.956634.

16.

Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.

Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.

Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.

17.

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.

Shi Y, Jin J, Wang X, Ji W, Guan X.

Neoplasia. 2019 Jun;21(6):533-544. doi: 10.1016/j.neo.2019.04.001. Epub 2019 Apr 24.

18.

Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2017 Dec;16(12):2881-2891. doi: 10.1158/1535-7163.MCT-17-0587. Epub 2017 Sep 13.

19.

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.

Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J.

Oncogene. 2011 Mar 24;30(12):1436-48. doi: 10.1038/onc.2010.509. Epub 2010 Nov 8.

PMID:
21057535
20.

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.

Wang Y, Xia H, Zhuang Z, Miao L, Chen X, Cai H.

Cell Death Dis. 2014 May 15;5:e1227. doi: 10.1038/cddis.2014.186.

Supplemental Content

Support Center